Signals, Powered By EquityPandit
Glenmark Pharmaceuticals has got the US health regulator’s final approval for generic version of Desonide cream that is used in treating a variety of skin conditions.
Glenmark Pharmaceuticals has said in a BSE filing that “Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (US FDA) for Desonide Cream, 0.05 percent, the generic version of Desonide Cream, 0.05 percent of Perrigo New York Inc.”
Glenmark has said that as per the IMS Health sales data for the 12 months to May 2017, Desonide Cream, 0.05 percent, achieved annual sales of approximately USD 44.6 million.
